Masonic Cancer Center, University of Minnesota

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Masonic Cancer Center, University of Minnesota sits in the top decile of US sponsors by registered trial count (#132 of 15,742 sponsors by registered trial count).

249 total trials 36 currently recruiting 127 completed early-phase tilt top decile by trial count

Masonic Cancer Center, University of Minnesota: 249 sponsored US clinical trials, 36 recruiting.

Masonic Cancer Center, University of Minnesota sponsors 249 registered US clinical trials on ClinicalTrials.gov, 36 of them currently recruiting, and 127 completed. 1 of these trials are in Phase 3-4 (later-stage) and 183 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 7 trials.

Top-decile sponsor footprint

Masonic Cancer Center, University of Minnesota ranks in the top decile of sponsors by registered trial count (#132 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

127 of 201 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (63.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

249 total, page 4 of 5

TERMINATED Phase 1

Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer

NCT00963872
COMPLETED Phase 1

Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs

NCT01033552
COMPLETED Phase 2

Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders

NCT01043640
TERMINATED Phase 1

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

NCT01012362
COMPLETED NA

Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer

NCT00895414
TERMINATED Phase 1

Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00903630
TERMINATED Phase 2

Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia

NCT00882206
TERMINATED Phase 2

Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders

NCT00869323
TERMINATED Phase 2

Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT00818649
TERMINATED Phase 2

Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML

NCT00871689
COMPLETED

Iron Overload in Patients Undergoing Donor Stem Cell Transplant

NCT00888316
TERMINATED Phase 2

Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca

NCT00784524
COMPLETED Phase 2

Allogeneic Transplantation For Severe Osteopetrosis

NCT00775931
COMPLETED Phase 2

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

NCT00726739
TERMINATED Phase 1

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

NCT00725062
COMPLETED Phase 1

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

NCT00703638
TERMINATED Phase 2

Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism

NCT00668564
TERMINATED Phase 2

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

NCT00652899
COMPLETED Phase 1

Intrathecal Enzyme Replacement for Hurler Syndrome

NCT00638547
TERMINATED Phase 1

Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia

NCT00643240
TERMINATED Phase 1

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

NCT00625729
TERMINATED Phase 2

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

NCT00617929
COMPLETED Phase 1

Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies

NCT00625092
TERMINATED Phase 2

Reduced Intensity AlloTransplant For Osteopetrosis

NCT00638820
COMPLETED Phase 2

Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA

NCT00455312
COMPLETED NA

Empowering Cancer Survivors Through Information Technology

NCT01593618
TERMINATED Phase 2

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

NCT00602446
COMPLETED Phase 1

T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer

NCT00602693
COMPLETED Phase 2

Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer

NCT00617188
TERMINATED Phase 1

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

NCT00376519
COMPLETED Phase 1

Clinical Trial of Trametes Versicolor in Women With Breast Cancer

NCT00680667
TERMINATED NA

Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa

NCT00478244
COMPLETED Phase 2

Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer

NCT00400803
COMPLETED Phase 1

Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

NCT00620295
COMPLETED Phase 2

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

NCT00381888
TERMINATED Phase 2

Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis

NCT00618540
COMPLETED Phase 2

Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors

NCT00432094
COMPLETED Phase 2

HSCT for High Risk Inherited Inborn Errors

NCT00383448
COMPLETED Phase 2

Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy

NCT00365547
TERMINATED Phase 2

Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

NCT00630565
COMPLETED Phase 2

CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer

NCT00610740
TERMINATED Phase 2

Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer

NCT00379197
COMPLETED Phase 2

TBI Dose De-escalation for Fanconi Anemia

NCT00352976
COMPLETED NA

PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma

NCT00346125
COMPLETED Phase 2

Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers

NCT00319748
TERMINATED Phase 2

Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer

NCT00376805
TERMINATED Phase 1

Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC

NCT00356941
TERMINATED Phase 2

Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

NCT00352118
TERMINATED Phase 2

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

NCT00354172
TERMINATED Phase 2

Study of Immune Response Modifier in the Treatment of Hematologic Malignancies

NCT00276159
← Previous Page 4 of 5 Next →

Phase Distribution

PhaseTrial count
Phase 1 76
Phase 2 107
Phase 3 1

Therapeutic Areas

Acute Myeloid Leukemia 7
Ovarian Cancer 6
Myelodysplastic Syndromes 5
Chronic Myelogenous Leukemia 4
Acute Lymphoblastic Leukemia 4
Myelodysplasia 3
Plasma Cell Leukemia 3
Fanconi Anemia 3
Breast Cancer 3
Lung Cancer 3

What is open in the Masonic Cancer Center, University of Minnesota pipeline

36 recruiting of 249 indexed (14% open); 127 completed (51%).

Phase mix: 1 late (III/IV) vs 183 early (I/II) (early-phase heavy).

Top condition: Acute Myeloid Leukemia (7 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Masonic Cancer Center, University of Minnesota: open-pipeline peers nationwide

Peers matched on 249 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Masonic Cancer Center, University of Minnesota sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 0%5%10%15%20% Total trials Recruiting share Masonic Cancer Center, University of MinnesotaUniversity of South FloridaBoston Medical CenterShireUniversity of CincinnatiModernaTXThe Cleveland ClinicUniversity of Wisconsin, MadisonDana-Farber Cancer Institute
Masonic Cancer Center, University of Minnesota sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Masonic Cancer Center, University of Minnesota sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 249 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Masonic Cancer Center, University of Minnesota page

249 registered trials is a research-attention snapshot, not an endorsement of Masonic Cancer Center, University of Minnesota or any single study.

  • 36 of Masonic Cancer Center, University of Minnesota's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Acute Myeloid Leukemia is the condition Masonic Cancer Center, University of Minnesota studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Masonic Cancer Center, University of Minnesota pipeline card: 249 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.